Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

This is a non-interventional extension study of up to 6 months for subjects completing the
Parent study. The Parent study is a Phase 3, multicenter study to assess the safety and
efficacy of 4 mg of CLS-TA administered via suprachoroidal injection compared to a sham
procedure in the treatment of subjects with macular edema associated with non-infectious
uveitis.

The study design of the Extension study includes 4 clinic visits over a maximum of 24 weeks.
Subject eligibility will be established at Visit 1 during the crossover day from the Parent
study to the extension study (Day 0). Follow-up visits will be conducted every 6 weeks up to
24 weeks (Visit 4). At Visit 4, subjects will have a final evaluation conducted 24 weeks
following study entry (48 weeks from Parent study randomization).

Inclusion Criteria:

- Enrolled in the Parent study, CLS1001-301, through Visit 8/Month 6

- Willing and able to provide written informed consent prior to any study procedures;
willing to comply with the instructions and attend all scheduled study visits

Exclusion Criteria:

- Received additional therapy for the treatment of uveitis or prohibited medication

- Require additional therapy for the treatment of uveitis or prohibited medication at
the time of the Crossover visit